Type I IFN–related NETosis in ataxia telangiectasia and Artemis deficiency
Open accessThe DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.
Abstract
Background: Pathological inflammatory syndromes of unknown etiology are commonly observed in ataxia telangiectasia (AT) and Artemis deficiency. Similar inflammatory manifestations also exist in patients with STING‐associated vasculopathy in infancy (SAVI). Objective: We sought to test the hypothesis that the inflammation‐associated manifestations observed in patients with AT and Artemis deficiency stem from increased type I IFN signature leading to neutrophil‐mediated pathological damage. Methods: Cytokine/protein signatures were determined by ELISA, cytometric bead array, or quantitative PCR. Stat1 phosphorylation levels were determined by flow cytometry. DNA species accumulating in the cytosol of patients' cells were quantified microscopically and flow cytometrically. Propensity of isolated polymorhonuclear granulocytes to form neutrophil extracellular traps (NETs) was determined using fluorescence microscopy and picogreen assay. Neutrophil reactive oxygen species levels and mitochondrial stress were assayed using fluorogenic probes, microscopy, and flow cytometry. Results: Type I and III IFN signatures were elevated in plasma and peripheral blood cells of patients with AT, Artemis deficiency, and SAVI. Chronic IFN production stemmed from the accumulation of DNA in the cytoplasm of AT and Artemis‐deficient cells. Neutrophils isolated from patients spontaneously produced NETs and displayed indicators of oxidative and mitochondrial stress, supportive of their NETotic tendencies. A similar phenomenon was also observed in neutrophils from healthy controls exposed to patient plasma samples or exogeneous IFN‐&agr;. Conclusions: Type I IFN–mediated neutrophil activation and NET formation may contribute to inflammatory manifestations observed in patients with AT, Artemis deficiency, and SAVI. Thus, neutrophils represent a promising target to manage inflammatory syndromes in diseases with active type I IFN signature. GRAPHICAL ABSTRACT Figure. No caption available.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Lood, C., Blanco, L. P., Purmalek, M. M., Carmona-Rivera, C., De Ravin, S. S., Smith, C. K., Malech, H. L., Ledbetter, J. A., Elkon, K. B., & Kaplan, M. J. (2016) · Nature Medicine · doi:10.1038/nm.4027 · Cited by 1,570
Aicardi–Goutières syndrome and the type I interferonopathies
Crow, Y. J., & Manel, N. (2015) · Nature Reviews Immunology · doi:10.1038/nri3850 · Cited by 925 · cited 1×
“SAVI and several other autoinflammatory/autoimmune diseases display a unique signature of type I IFN activity, suggesting a common underlying mechanism of clinical pathologies, including systemic inflammation, skin lesions, and pulmonary disease.(1-4,27) The pathogenic mechanism(s) behind the type I IFN–inflicted tiss…”
BackgroundHärtlova, A., Erttmann, S. F., Raffi, F. A., Schmalz, A. M., Resch, U., Anugula, S., Lienenklaus, S., Nilsson, L. M., Kröger, A., Nilsson, J. A., et al. (2015) · Immunity · doi:10.1016/j.immuni.2015.01.012 · Cited by 716
Rodero, M. P., & Crow, Y. J. (2016) · Journal of Experimental Medicine · doi:10.1084/jem.20161596 · Cited by 433
DNA damage-induced type I interferon promotes senescence and inhibits stem cell function
Yu, Q., Katlinskaya, Y. V., Carbone, C. J., Zhao, B., Katlinski, K. V., Zheng, H., Guha, M., Li, N., Chen, Q., Yang, T., et al. (2015) · Cell Reports · doi:10.1016/j.celrep.2015.03.069 · Cited by 260 · cited 3×
“To detect TMEM173 gene mutations, exons (3-8) were amplified, followed by bidirectional Sanger sequencing (see the Methods section in this article’s Online Repository at www.”
BackgroundMethod
Cited by
The cGAS–cGAMP–STING pathway connects DNA damage to inflammation, senescence, and cancer
Li, T., & Chen, Z. J. (2018) · Journal of Experimental Medicine · doi:10.1084/jem.20180139 · Cited by 1,293
“Interestingly, the resulting vascular and pulmonary syndrome of SAVI resemble those of some DDR deficiency– associated autoinflammation, such as A-T and Artemis deficiency (Gul et al., 2017), consistent with the notion that these genetic disorders affect the same signaling pathway.”
BackgroundInflammatory microenvironment remodelling by tumour cells after radiotherapy
McLaughlin, M., Patin, E. C., Pedersen, M., Wilkins, A., Dillon, M. T., Melcher, A. A., & Harrington, K. J. (2020) · Nature Reviews Cancer · doi:10.1038/s41568-020-0246-1 · Cited by 883
The type I interferonopathies: 10 years on
Crow, Y. J., & Stetson, D. B. (2022) · Nature Reviews Immunology · doi:10.1038/s41577-021-00633-9 · Cited by 489
Neutrophil extracellular traps: from physiology to pathology
Hidalgo, A., Libby, P., Soehnlein, O., Aramburu, I. V., Papayannopoulos, V., & Silvestre-Roig, C. (2022) · Cardiovascular Research · doi:10.1093/cvr/cvab329 · Cited by 401
DNA damage and repair in age-related inflammation
Zhao, Y., Simon, M., Seluanov, A., & Gorbunova, V. (2023) · Nature Reviews Immunology · doi:10.1038/s41577-022-00751-y · Cited by 372
Targeting the DNA damage response in immuno-oncology: developments and opportunities
Chabanon, R. M., Rouanne, M., Lord, C. J., Soria, J.-C., Pasero, P., & Postel-Vinay, S. (2021) · Nature Reviews Cancer · doi:10.1038/s41568-021-00386-6 · Cited by 293
Mistry, P., Nakabo, S., O’Neil, L., Goel, R. R., Jiang, K., Carmona-Rivera, C., Gupta, S., Chan, D. W., Carlucci, P. M., Wang, X., et al. (2019) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1908576116 · Cited by 278
Research Advances in How the cGAS-STING Pathway Controls the Cellular Inflammatory Response
Wan, D., Jiang, W., & Hao, J. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.00615 · Cited by 270
Metadata
- Authors
- Gul, E., Sayar, E. H., Gungor, B., Eroglu, F. K., Surucu, N., Keles, S., Guner, S. N., Findik, S., Alpdundar, E., Ayanoglu, I. C., Kayaoglu, B., Geckin, B. N., Sanli, H. A., Kahraman, T., Yakicier, C., Muftuoglu, M., Oguz, B., Cagdas Ayvaz, D. N., Gursel, I., Ozen, S., Reisli, I., & Gursel, M.
- Venue
- Journal of Allergy and Clinical Immunology
- Publisher
- Elsevier BV
- Published
- 2018-07
- Volume
- 142
- Issue
- 1
- Pages
- 246-257
- ISSN
- 0091-6749 (ISSN-L)
- OpenAlex
- W2769972938
- Cited by
- 67
- References
- 5
- FWCI
- 1.88
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.